{
    "nct_id": "NCT03377361",
    "official_title": "A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers",
    "inclusion_criteria": "* Histologically or cytologically confirmed previously treated metastatic colorectal cancer with adenocarcinoma histology and in Stage IV per American Joint Committee on Cancer (version 4.0) at study entry\n* Microsatellite status should be performed per local standard of practice, immunohistochemistry (IHC) and/or PCR. If IHC results are equivocal, PCR is required for determining microsatellite stable (MSS) status\n* Must have measurable disease per RECIST 1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 at screening and on cycle 1 day 1 (C1D1)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* BRAF V600 mutant colorectal cancer\n* Active brain metastases or leptomeningeal metastases\n* Active, known or suspected autoimmune disease\n* Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration\n* History of interstitial lung disease or pneumonitis\n* Prior treatment with immune checkpoint inhibitors and mitogen-activated protein kinase enzymes (MEK) inhibitors\n* History of allergy or hypersensitivity to study drug components\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}